SIGNUP FOR
NEWSLETTER
NASDAQ: HSDT
Call us: +1 877-564-0008
About
Back
Overview
Management Team
Board of Directors
Scientific Interests
Divisions
Back
Overview
Helius Medical
Back
The PoNS Device
Investor Relations
Back
Overview
Stock Info
Events
Back
Upcoming Events
Past Events
Code of Conduct
Corporate Documents
Committee Charters
SEC Filings
Financial Information
Investor FAQ
Newsroom
Back
News Releases
Back
2022
2021
2020
2019
2018
Archive
Back
2017
2016
2015
2014
In the News
Back
HMT Coverage
Related Science
Media Resources
Our Research
Back
Overview
Clinical Trials
Peer-Reviewed Publications
Words to Know
Research Partners
Contact
Back
Contact HMT
Subscribe Newsletter
Careers
Back
Home
Newsroom
News Releases
Menu
News Releases
2022
2021
2020
2019
2018
Archive
2017
2016
2015
2014
In the News
HMT Coverage
Related Science
Media Resources
Stock Quote - HSDT
*Delayed quote courtesy of Google.
2020 News
Filters
- Select Tag -
Clinical News
Corporate News
Filter
List of articles in category 2020 News
Title
Date
Helius Medical Technologies, Inc. Announces Reverse Stock Split
31 Dec, 2020
Helius Medical Technologies, Inc. Reports Third Quarter of Fiscal Year 2020 Financial Results
12 Nov, 2020
Helius Medical Technologies, Inc. to Present at Upcoming Investor Conferences in November
05 Nov, 2020
Helius Medical Technologies, Inc. Announces the Expansion to a Total of 27 Authorized PoNS Treatment™ Clinic Locations Across Canada
04 Nov, 2020
Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020
02 Nov, 2020
Helius Medical Technologies Announces Closing of $3.4 Million Private Placement
26 Oct, 2020
Helius Medical Technologies Announces $3.4 Million Private Placement
21 Oct, 2020
Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
19 Oct, 2020
Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights
14 Oct, 2020
Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
08 Oct, 2020
Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury
08 Sep, 2020
Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September
31 Aug, 2020
Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors
25 Aug, 2020
Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results
12 Aug, 2020
Helius Medical Technologies to Release Second Quarter of Fiscal Year 2020 Financial Results on August 12, 2020
10 Aug, 2020
Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020
06 Aug, 2020
Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit
14 Jul, 2020
Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th
05 Jun, 2020
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
12 May, 2020
Helius Medical Technologies, Inc. Reports First Quarter of Full Year 2020 Financial Results; Updates Full Year 2020 Outlook
07 May, 2020
UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI
30 Apr, 2020
Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI
30 Apr, 2020
Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020
22 Apr, 2020
Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors
22 Apr, 2020
Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)
24 Mar, 2020
Helius Medical Technologies Announces $2.2 Million Registered Direct Offering
18 Mar, 2020
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook
12 Mar, 2020
Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics
09 Mar, 2020
Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and New US Regulatory Prioritization for MS
02 Mar, 2020
Helius Medical Technologies CEO Philippe Deschamps to Deliver Congressional Briefing on the Latest Technologies, Innovations and Policies in Clinical Neuroscience
24 Feb, 2020
Helius Medical Technologies Inc. Welcomes Cline Medical Centre as an Authorized PoNS Treatment™ Clinic in Nanaimo, BC
07 Feb, 2020
Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 12, 2020
05 Feb, 2020
Helius Medical Technologies, Inc. Issues a Clarification to the News Release Regarding the Agreement with the University Health Network (UHN) Issued at 7:05 am January 16, 2020
16 Jan, 2020
Helius Medical Technologies, Inc. and University Health Network (UHN) Have Signed an Agreement for UHN and three Neuro-Rehabilitation Centers to Perform a Clinical Experience Program of the PoNS™ Device in Canada
16 Jan, 2020
Helius Medical Technologies Awarded Pioneer Technology Development Award
10 Jan, 2020
Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment
19 Dec, 2019